Skip to content

Evaluating of safety and efficacy of Stylux REDENSITY ® mesogel

Evaluating of safety and efficacy of Stylux REDENSITY ® mesogel (Novajen Daru CO) for improvement of skin hydration and elasticity”

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190210042676N31
Enrollment
20
Registered
2024-04-01
Start date
2024-04-20
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin hydration. Changes in skin texture

Interventions

Intervention group: 2 sessions with 2-3 cc of "Stylux Redensity ®" injectable mesogel made by Novajen Daru CO, with an interval of 3 to 4 weeks. Each Stylux Redensity ® pre-filled syringe contains: Hy

Sponsors

Novajen Daru
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age between 21 and 55years old Present visible signs of skin ageing symptoms mainly skin dryness skin roughness, loss of elasticity and appearance of fine lines Possibility to accompany the visit plans and study process. Signing an informed consent form and agreed to follow up.

Exclusion criteria

Exclusion criteria: Previous treatment with hyaluronic acid fillers in the facial area within the past year Systemic diseases affecting skin health such as collagen vascular diseases, diabetes, hypothyroidism, as well as liver and renal failure Experience with RF, rejuvenation lasers or intense pulsed light in the past 6 months History of systemic use of skin-related medicine such as glucocorticoids, isotretinoin, immunomodulators and hormonal medicine in the past 3 months Currently pregnant or lactating Smoking in the past two years

Design outcomes

Primary

MeasureTime frame
Stratum corneum hydration. Timepoint: Before intervention, 4 and 12 weeks after the last injection. Method of measurement: Corneometry by MPA 580.

Secondary

MeasureTime frame
Skin elasticity. Timepoint: Before intervention, 4 and 12 weeks after the last injection. Method of measurement: Cutometery.;Trans Epidermal Water Loss. Timepoint: Before intervention, 4 and 12 weeks after the last injection. Method of measurement: Tewameter.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026